Skip to main content

Erenumab Effective, Safe for Rosacea-Linked Erythema, Flushing

Medically reviewed by Carmen Pope, BPharm. Last updated on April 17, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, April 17, 2024 -- The anticalcitonin gene-related peptide-receptor monoclonal antibody erenumab is effective and safe for treatment of rosacea-associated erythema and flushing, according to a study published online April 17 in JAMA Dermatology.

Nita K.F. Wienholtz, M.D., Ph.D., from Copenhagen University Hospital-Rigshospitalet in Denmark, and colleagues examined the effectiveness, tolerability, and safety of erenumab for treatment of rosacea-associated erythema and flushing in a single-center, nonrandomized trial involving adults with rosacea with at least 15 days of moderate-to-severe erythema and/or moderate-to-extreme flushing. Participants received 140 mg erenumab subcutaneously every four weeks for a period of 12 weeks; safety was assessed at week 20.

Thirty participants were included; 27 completed the study. The researchers observed a reduction of −6.9 days in the mean number of days with moderate-to-extreme flushing, from 23.6 days at baseline. For moderate-to-severe erythema, the mean number of days was reduced by −8.1 from 15.2 at baseline. Adverse events included transient mild-to-moderate constipation, transient worsening of flushing, bloating, and upper respiratory tract infection (33, 13, 10, and 10 percent, respectively). One participant discontinued the study due to a serious adverse event, deemed unrelated to the study, and two withdrew consent due to time constraints.

"The results also suggest that erenumab is generally well tolerated, with mild and/or transient adverse effects," the authors write. "Larger randomized, controlled, double-blind studies are necessary to confirm these findings and to investigate the long-term effects of erenumab treatment."

Several authors disclosed ties to pharmaceutical companies, including Novartis Pharma, which funded the study.

Abstract/Full Text (subscription or payment may be required)

Editor's Note (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

Social Stigma Associated With Adult Facial Acne

FRIDAY, Oct. 20, 2023 -- Acne patterns significantly influence how individuals are perceived in social settings, according to a study presented at the annual meeting of the...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.